369 related articles for article (PubMed ID: 1486771)
21. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
22. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
23. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment.
Milman N; Kirchhoff M; Jørgensen T
Ann Hematol; 1992 Aug; 65(2):96-102. PubMed ID: 1511065
[TBL] [Abstract][Full Text] [Related]
24. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
25. Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood.
Inauen W; Stocker G; Haeberli A; Straub PW
Contraception; 1991 May; 43(5):435-46. PubMed ID: 1833126
[TBL] [Abstract][Full Text] [Related]
26. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
27. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel.
Rekers H
Acta Obstet Gynecol Scand; 1988; 67(2):171-4. PubMed ID: 2972160
[TBL] [Abstract][Full Text] [Related]
28. Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol.
Lammers P; op ten Berg M
Acta Obstet Gynecol Scand; 1991; 70(6):497-500. PubMed ID: 1837199
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users.
Brill K; Norpoth T; Schnitker J; Albring M
Contraception; 1991 Feb; 43(2):101-10. PubMed ID: 2040166
[TBL] [Abstract][Full Text] [Related]
30. The influence of copper surface area on menstrual blood loss and iron status in women fitted with an IUD.
Milsom I; Rybo G; Lindstedt G
Contraception; 1990 Mar; 41(3):271-81. PubMed ID: 2323218
[TBL] [Abstract][Full Text] [Related]
31. Laboratory criteria for menopause in women using oral contraceptives.
Creinin MD
Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
[TBL] [Abstract][Full Text] [Related]
32. Levels of protein S during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
Jespersen J; Nielsen MT
Gynecol Obstet Invest; 1989; 28(2):82-6. PubMed ID: 2529199
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
Bannemerschult R; Hanker JP; Wünsch C; Fox P; Albring M; Brill K
Contraception; 1997 Nov; 56(5):285-90. PubMed ID: 9437556
[TBL] [Abstract][Full Text] [Related]
34. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
[TBL] [Abstract][Full Text] [Related]
35. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
36. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
37. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
[TBL] [Abstract][Full Text] [Related]
38. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
39. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
Winkler UH; Schindler AE; Endrikat J; Düsterberg B
Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
[TBL] [Abstract][Full Text] [Related]
40. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
